{"589724":{"#nid":"589724","#data":{"type":"event","title":"PhD Proposal by Jiaying Liu","body":[{"value":"\u003Cp\u003E\u003Cstrong\u003EJiaying Liu\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003EBME PhD Thesis Proposal Presentation\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003EDate:\u0026nbsp;\u003C\/strong\u003EMonday, April 17th\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003ETime\u003C\/strong\u003E:\u0026nbsp;1:00pm\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003ELocation\u003C\/strong\u003E: EBB CHOA seminar\u0026nbsp;room, Georgia Tech\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003EAdvisor:\u0026nbsp;\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003EDr.Krishnendu Roy\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003ECommittee\u003C\/strong\u003E:\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003EDr.\u0026nbsp;M.G.Finn (Chemistry and Biochemistry)\u003C\/p\u003E\r\n\r\n\u003Cp\u003EDr.Robert Guldberg\u003C\/p\u003E\r\n\r\n\u003Cp\u003EDr.Ravi Kane\u003C\/p\u003E\r\n\r\n\u003Cp\u003EDr.Susan Thomas\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003ETitle\u003C\/strong\u003E:\u0026nbsp;\u003Cstrong\u003EDesign and Development of Synthetic Nanoparticle Antibodies to Deplete Selected Target Cells for Cancer Immunotherapy\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u003Cstrong\u003EAbstract:\u0026nbsp;\u003C\/strong\u003E\u003C\/p\u003E\r\n\r\n\u003Cp\u003EMonoclonal antibody(mAb) treatment for cancer has been developed for over three decades and has proved its efficacy in a number of hematological malignancies and solid tumors.\u0026nbsp;A handful of available mAbs (e.g.,atezolizumab) take advantage of antibody-dependent immune responses to eliminate the suppressive cells\/proteins and restore anti-cancer immunity. Some other mAbs (e.g.,Trastuzumab,\u0026nbsp;Rituximab), which are able to bind to cancer-associated antigens(e.g. Her2), can kill tumor targets by eliciting antibody-dependent cellular cytotoxicity\/phagocytosis (ADCC\/ADCP). However, the application of monoclonal antibodies as therapeutics is greatly limited by their complicated production procedure,\u0026nbsp;high production cost as well as\u0026nbsp;limited deep\u0026nbsp;tissue penetration.\u0026nbsp;Additionally, many important immunological targets, such as\u0026nbsp;myeloid-derived suppressor cells (MDSCs) and regulatory T cells, still lack direct\u0026nbsp;mAb treatments. A few types of artificial antibodies, including nanobody, minibody and peptibody, which are developed by alternation of the orignal mAb structures, achieved higher tumor-to-blood distribution\u0026nbsp;ratio, but still suffer from other drawbacks associated with their\u0026nbsp;production and application similar to those of mAbs. We propose to develop synthetic nanoparticle antibodies (SNAbs) , which are Janus nanoparticles multi-valently displaying both binding ligands for the selected targets and Fc-mimicking ligands that can activate Fc receptors on the immune effector cells.\u0026nbsp;Our primary hypothesis is that the designed SJNAs could induce ADCC\/ADCP of cellular targets efficiently both\u0026nbsp;\u003Cem\u003Ein vitro\u003C\/em\u003E\u0026nbsp;and\u0026nbsp;\u003Cem\u003Ein vivo\u003C\/em\u003E. Investigation will be conducted on two types of SNAbs: one for MDSCs and one for Her2-expressing cancer cells. We will perform both in vitro study on Fc-receptor-mediated signaling triggered by the SNAbs as well as in vivo assessment of their therapeutic potential in murine tumor models.\u0026nbsp;We believe that SNAbs\u0026nbsp;can\u0026nbsp;not only be\u0026nbsp;a functional alternative to conventional mAbs for target cell depletion in cancer, but also possess potential advantages including simpler fabrication procedure, flexible platform and better tumor penetration.\u0026nbsp;\u003C\/p\u003E\r\n\r\n\u003Cp\u003E\u0026nbsp;\u003C\/p\u003E\r\n","summary":null,"format":"limited_html"}],"field_subtitle":"","field_summary":"","field_summary_sentence":[{"value":"Design and Development of Synthetic Nanoparticle Antibodies to Deplete Selected Target Cells for Cancer Immunotherapy"}],"uid":"27707","created_gmt":"2017-04-04 12:36:34","changed_gmt":"2017-04-04 12:36:34","author":"Tatianna Richardson","boilerplate_text":"","field_publication":"","field_article_url":"","field_event_time":{"event_time_start":"2017-04-17T14:00:00-04:00","event_time_end":"2017-04-17T16:00:00-04:00","event_time_end_last":"2017-04-17T16:00:00-04:00","gmt_time_start":"2017-04-17 18:00:00","gmt_time_end":"2017-04-17 20:00:00","gmt_time_end_last":"2017-04-17 20:00:00","rrule":null,"timezone":"America\/New_York"},"extras":[],"groups":[{"id":"221981","name":"Graduate Studies"}],"categories":[],"keywords":[{"id":"102851","name":"Phd proposal"}],"core_research_areas":[],"news_room_topics":[],"event_categories":[{"id":"1788","name":"Other\/Miscellaneous"}],"invited_audience":[{"id":"78771","name":"Public"}],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[],"email":[],"slides":[],"orientation":[],"userdata":""}}}